Macro Group Pharma reported EGP 68.9 mn in net income in 1H 2025, compared to a net loss of EGP 88.8 mn in the same period last year, according to the company’s latest earnings release (pdf). “Growth was driven by higher volumes, the rollout

of our pricing strategy in March, and stronger brand-led marketing, alongside improved inventory management and supply chain efficiency,” Chairman Ahmed Elnayeb said.

(Tap or click the headline above to read this story with all of the links to our background as well as external sources.)

Revenues more than doubled during the first half of the year, growing 165% y-o-y to record EGP 412 mn on the back of a 146% y-o-y rise in sales volumes to 8 mn units and targeted price adjustments. Export revenues also rose sharply to EGP 17.5 mn — representing 4% of total revenue — up from EGP 6.3 mn in 1H24.

Looking ahead: “We remain focused on driving growth, enhancing profitability, and expanding our presence both domestically and internationally. With a strong brand, innovative pipeline, and robust distribution network, Macro is well-positioned to sustain its recovery and deliver long-term value for stakeholders,” Elnayeb said.

Tags: